Klinische Wirksamkeit von OeKolp^®

Wolf, A. (1991). Hormonelle Altersveränderungen aus der Sicht des Gynäkologen. Fortschr Med, 109(18), S. 28-34.

Haspels, A., Luisi, M., & Kicovic, P. (1981, Dec). Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas, 3(3-4), pp. 321-7.

Luisi, M., Franchi, F., & Kicovic, P. (1980, Dec). A group-comparative study of effects of Ovestin cream versus Premarin cream in post-menopausal women with vaginal atrophy. Maturitas, 2(4), pp. 311-9.

Henriksson, L., et al. (1994, Sep). A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol, 171(3), pp. 624-32.

Bottiglione, F., Volpe, A., Esposito, G., & Aloysio, D. (1995, Nov). Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. Maturitas, 22(3), pp. 227-32.

Trevoux, R., van der Velden, W., & Popović, D. (1982, Apr-Jun). Ovestin vaginal cream and suppositories for the treatment of menopausal vaginal atrophy. Reproduccion, 6(2), pp. 101-6.

Fink, R., et al. (1985). Vaginal oestriol - Effective menopausal therapy not associated with endometrial hyperplasia. J Gynaecol Endocrinol, 1(1-2), pp. 1-11.

Kicovic, P., et al. (1980, Dec). The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects. Maturitas, 2(4), pp. 275-82.

Griesser, H., et al. (2012, Apr). Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas, 71(4), pp. 360-8.

De Leo, V., Caruso, S., Scolaro, V., & Cianci, A. (2009, Oct). Low dose oral contraceptives: 30 microg are still used? Minerva Ginecol, 61(5), pp. 453-8.

Buhling KJ, et al. (2012). Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. Arzneimittel-Forschung;62(8):378-383.

Clocuh, Y. (1980). Oestrogengabe als hormonelle Aufhellung zur Abklärung atrophischer Zellabstriche. Geburtsh Frauenheilk, 40, S. 1121-9.

Vooijs GP, Geurts TB. (1995). Review of the endometrial safety during intravaginal treatment with estriol. European journal of obstetrics, gynecology, and reproductive biology;62(1):101-106.

Weiderpass, E., et al. (1999, May). Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet, 353(9167), pp. 1824-8.

Lindahl, S. (2014, Mar). Reviewing the options for local estrogen treatment of vaginal atrophy. Int J Womens Health, 13(6), pp. 307-12.

Kuhl H. (1998). Pharmakologie von Sexualsteroiden. Gynäkologe; 31:832-847.

Magnusson, C., et al. (1999, May). Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer, 81(3), pp. 339-44.

Rossouw JE, et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA ;288(3):321-333.

Anderson GL, Limacher M, Assaf AR, et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA;291(14):1701-1712.

Mueck AO (2015). Anwendungsempfehlungen zur Hormonsubstitution in Klimakterium und Postmenopause. Frauenarzt 56(8):657-660.

Le Ray, I., et al. (2012, Sep). Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat, 135(2), pp. 603-9.

Buchholz S, et al. (2015). Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric;18(2):252-259.

The 2017 hormone therapy position statement of The North American Menopause Society (2017). Menopause ;24(7):728-753.

Donders, G., et al. (2014, Jun). Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat, 145(2), pp. 371-9.